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Abstract
Background: Selected patients with peritoneal carcinomatosis (PC) from colorectal cancer (CRC) benefit from
cytoreductive surgery (CRS) combined with intraperitoneal chemoperfusion (IPC). However, even after optimal
cytoreduction, systemic and locoregional recurrence are common. Perioperative chemotherapy with bevacizumab
(BEV) may improve the outcome of these patients.
Methods/Design: The BEV-IP study is a phase II, single-arm, open-label study aimed at patients with colorectal or
appendiceal adenocarcinoma with synchronous or metachronous PC. This study evaluates whether perioperative
chemotherapy including BEV in combination with CRS and oxaliplatin-based IPC results in acceptable morbidity and
mortality (primary composite endpoint). Secondary endpoints are treatment completion rate, chemotherapy-related
toxicity, pathological response, progression free survival, and overall survival.
Discussion: The BEV-IP trial is the first prospective assessment of the safety and efficacy of perioperative chemotherapy
combined with anti-angiogenic treatment in patients undergoing CRS and IPC for colorectal peritoneal metastases.
Trial registration: ClinicalTrials.gov Identifier: NCT02399410 EudraCT number: 2015-001187-19 (registered March 9, 2015).
Keywords: Bevacizumab, Colorectal cancer, Cytoreductive surgery, HIPEC, Perioperative chemotherapy, Peritoneal
carcinomatosis
Background
Peritoneal carcinomatosis from colorectal cancer
Colorectal cancer (CRC) represents a major cause of
cancer related mortality worldwide [1]. Over the past
decades, advances in surgical management and identifi-
cation of novel therapeutic targets have led to significant
progress in the survival of patients with metastatic dis-
ease [2]. A notable exception, however, are patients with
peritoneal carcinomatosis (PC) who are not only at risk
of debilitating symptoms but in whom modern chemo-
therapy and targeted therapy are much less effective [3].
The epidemiology and risk factors for PC in CRC are
not well established. In retrospective single centre series,
the reported incidence of PC is approximately 7 % of pa-
tients at primary surgery, and 4 % to 19 % of patients
during follow-up after curative surgery [4]. In a recent
population-based cohort study from Stockholm County
in Sweden, 4.8 % of 11,124 CRC patients had PC as the
first and only site of metastatic disease [5]. Results
from this cohort study as well as those from a large
CRC cohort study in The Netherlands have identified
several independent clinicopathological risk factors for
synchronous PC: colon versus rectal cancer, right
colon cancer, T stage, N stage, emergency and non-
radical resection, younger age, and mucinous tumours
[6]. Recent molecular research in a series of 524 CRC
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patients has indicated that those with BRAF mutant
cancers (11 %) are at higher risk of PC (46 % vs
24 %, P = 0.001) [7].
Systemic chemotherapy
When untreated, the outlook of patients with PC from
CRC is grim. The French multicentre EVOCAPE 1 study
found a median survival in patients with PC of 5.2 months
[8]. The predictive and prognostic significance of PC in
metastatic CRC (mCRC) patients treated with palliative
chemotherapy with or without a targeted agent are diffi-
cult to assess since the presence of PC is usually not speci-
fied in the reported trials. There is a lack of high level
evidence on systemic anticancer therapy in patients with
mCRC limited to the peritoneal surfaces. Nevertheless, a
number of observations can be made from the available
literature. First, systemic chemotherapy prolongs survival
in PC patients compared to best supportive care. In a
series of 167 PC patients, Pelz et al. observed a median
survival of 5 months in patients not receiving chemo-
therapy versus 11 and 12 months in patients receiving
5-fluorouracil (5-FU)/leucovorin (LV) and oxaliplatin
(OX)/irinotecan (IRI)-based chemotherapy, respectively
(P = 0.026 versus no chemotherapy) [9]. In the CAIRO 2
study, which randomized mCRC patients to either cape-
citabine, OX, and bevacizumab (BEV) or the same regi-
men plus cetuximab, the subgroup of patients with PC
had a median survival of 15.2 months [10]. However, sev-
eral authors have shown that the presence of PC repre-
sents an adverse predictive factor in patients treated with
modern chemotherapy. Franko and colleagues analysed
the outcome of PC versus other metastatic sites in mCRC
patients included in the North Central Cancer Treatment
Group trials N9741 (comparing FOLFIRI, FOLFOX, and
IROX) and N9841(comparing IRI versus FOLFOX) [11].
They found that overall (OS) and progression free survival
(PFS) were significantly worse in patients with PC (95 %
confidence interval of the hazard ratio 1.2–1.5; P < 0.001
and 1.1–1.3; P = 0.001, respectively).
Hyperthermic intraperitoneal chemoperfusion (HIPEC)
HIPEC was first described in an animal model in 1974
by Euler [12]. The first clinical application of combined
cytoreductive surgery (CRS) and HIPEC was reported in
1980 by Spratt and colleagues, who treated a young pa-
tient suffering from pseudomyxoma peritonei with exten-
sive surgery followed by intraperitoneal chemoperfusion
(IPC) of Thiotepa under hyperthermic conditions using a
delivery system consisting of a heat exchanger and pump
[13]. After the procedure, the drains were left in place and
5 days later another HIPEC procedure with methotrexate
was performed. In that publication, the authors stressed
the importance of removing free floating cancer cells by
the microfilters in the perfusion circuit. The advantage of
intraoperative (as opposed to adjuvant) chemoperfusion is
the possibility to achieve optimal chemotherapy exposure
of all peritoneal surfaces at risk of peritoneal seeding. The
use of hyperthermia is based on several observations. First,
hyperthermia is selectively cytotoxic for malignant cells
[14]. Second, the cytotoxicity of several chemotherapeutic
agents such as the platinum compounds and the alkylating
drugs is enhanced by hyperthermia [15]. Third, hyperther-
mia enhances tissue perfusion and oxygenation and may
improve drug penetration. Los and colleagues demon-
strated a significant increase in peritoneal tumour plat-
inum concentrations when intraperitoneal (IP) cisplatin
(CIS) therapy was combined with regional hyperthermia
(41.5 °C) in a rat colon cancer model [16].
Table 1 summarizes the most important clinical studies
in CRC published so far. Only one randomized prospect-
ive trial has evaluated palliative treatment versus surgery
and HIPEC in PC from CRC. Verwaal and co-authors re-
ported a randomized controlled trial comparing systemic
5FU/LV and palliative surgery when required versus ex-
tensive CRS and HIPEC using mitomycin C (35 mg/m2)
followed by systemic 5FU/LV in patients with PC from
CRC [17, 18]. The median disease specific survival was
12.6 months in the control arm and 22.2 months in the
CRS with HIPEC arm (P = 0.028); survival was signifi-
cantly better in patients with no more than five of seven
abdominal regions affected and in patients in whom a
macroscopically complete resection was achieved. The sig-
nificance of this trial is somewhat limited by the use of
systemic chemotherapy that is no longer regarded as the
standard of care in this setting and by the fact that the
question whether extensive CRS in itself (without added
HIPEC) would achieve a similar outcome remains un-
answered. The results from a multinational retrospective
analysis of 506 patients with PC from CRC treated with
CRS and HIPEC showed a median OS of 19 months; pa-
tients in whom a complete cytoreduction was achieved
had a median OS of 32.4 months [19]. Multivariate ana-
lysis revealed that other variables associated with survival
gain were treatment by a second procedure, limited disease
extent, age < 65 years and use of adjuvant chemotherapy.
A systematic review performed by Yan et al. demonstrated
that with complete cytoreduction a median OS from 28 to
60 months and 5-year OS ranging from 22 to 49 % may be
reached [20]. Similar results were obtained in a Belgian
and an Italian multicentre registry [21, 22]. Overall, the
quality of the available evidence is low, but it is reasonable
to assume that in selected patients in whom complete
cytoreduction can be achieved a significant prolongation
of survival is possible.
VEGF, Bevacizumab, and peritoneal carcinomatosis
The vascular endothelial growth factor A (VEGF-A)
plays a central role in tumour associated angiogenesis
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and in the pathogenesis of malignant ascites [23]. BEV
(Avastin®, Genentech/Roche) is a humanized monoclonal
antibody against circulating VEGF-A. The potential role
of inhibiting VEGF using BEV in patients with PC from
CRC is based on several theoretical considerations. First,
the combination of BEV with doublet (combination)
chemotherapy is considered an active first line strategy
in patients with mCRC [24]. Since many patients with
isolated PC from CRC harbour undetected systemic dis-
ease and will eventually recur, the addition of potent sys-
temic therapy to a locoregional approach such as CRS
with HIPEC is warranted. Second, BEV is known to
result in the lowering of the tumour’s interstitial fluid
pressure by vascular normalization, which may result in
enhanced delivery of IP chemotherapy [25–27]. Third,
preclinical and early clinical data demonstrate a role for
BEV in the treatment of PC and/or ascites from CRC or
ovarian cancer [28–31]. In a recent clinical study, Passot
and colleagues determined intravenous (IV) and IP VEGF
levels before and after CRS and HIPEC [32]. They found
that the IP VEGF concentration increased significantly
after surgery and that neoadjuvant BEV was associated
with a lower IP VEGF level in a multivariate model. Fi-
nally, neoadjuvant combination therapy with BEV may re-
sult in downstaging of disease extent, possibly leading to
improved outcome. In colorectal liver metastases, neoad-
juvant BEV combined with OX-based chemotherapy was
shown to result in enhanced pathological response and
improved PFS and OS [33]. Recent data from Ghent
University Hospital analysing the survival rate of a
cohort of 166 CRC patients treated with CRS and
HIPEC showed that neoadjuvant combination chemother-
apy with BEV was significantly associated with better OS
in multivariate analysis [34]. In addition, we recently dem-
onstrated that pretreatment with BEV leads to a markedly
reduced IFP in a mouse HT29 CRC model of IPC with
OX, which may allow for deeper penetration and higher
tumour drug concentration [35].
A potential drawback of perioperative BEV is the risk
of increased surgical morbidity. In a French multicentre
retrospective study, the addition of BEV to neoadjuvant
chemotherapy resulted in a significantly increased rate
of major morbidity (34 vs. 19 %, P = 0.020) [36]. There
were no differences in postoperative mortality or anasto-
motic leak rate. Also, both groups were significantly dif-
ferent in terms of associated liver resection (twice more
common in the BEV group) and chemoperfusion drug
regimen. In general, however, perioperative use of BEV
is considered relatively safe. A recent review suggested
that the overall risk of serious BEV related adverse
events in surgical patients is very low, provided that a
time frame of six weeks is respected [37].
The aim of the BEV-IP trial is to test the hypothesis
that perioperative chemotherapy combined with BEV
results in acceptable morbidity and mortality.
Methods/Design
Study design
The BEV-IP study is a phase II, single-arm, open-label
study. The study was initiated by the Department of
Gastrointestinal Surgery of the Ghent University Hospital
in collaboration with the Department of Surgical
Table 1 Clinical studies of HIPEC in patients with peritoneal carcinomatosis from colorectal origin
Author N IP chemo (mg/m2) Mb (%) Mt (%) RR (%) HS (d) MS (m) prognostic variables in multivariate analysis
CRT
Verwaal [16, 17] 49a MMC 35 - 8 - 29 22.3 >5/7 regions affected; CC
Multicentre
Elias [22] 523b MMC 30–50, CIS 50–100
OX 360–460, IRN 200
31 3.3 - 18 30.1 PCI, CC, nodal status, adjuvant chemotherapy
Glehen [18] 506c MMC, CIS, OX 23 4 10.7 - 19.2 PCI, CC, adjuvant chemotherapy, age <65y
Hompes [20] 48 OX 460 52 0 21 20 NR -
Cavaliere [21] 146 CIS 25, OX 460, MMC 33 27 2.7 - 20 21 CC, liver metastasis
Quenet [23] 146 OX 300–460, IRN 200 47 4 - - 41 PCI, nodal status
Monocentric
Franko [24] 67 MMC 40 - - - - 35 -
Cashin [25] 69 MMC 30, OX 460, IRN 360 40.6 4.3 - - 34 -
Shen [26] 77 MMC 30-40 30 12 - 10 16 CC, bowel obstruction, ascites
Vaira [27] 40 CIS 100, MMC 16–35, OX 460 55 2.5 23 - - -
Ceelen [28] 166 OX 200–460, MMC 35 35 2.4 - - 27 CC, neoadjuvant therapy with BEV
BEV bevacizumab, CC completeness of cytoreduction, CIS cisplatin, HIPEC hyperthermic intraperitoneal chemoperfusion, HS hospital stay, IP intraperitoneal, IRN irinotecan;
Mb postoperative morbidity, MMC mitomycin C; MS median survival in months, Mt postoperative mortality, NR not reached, OX oxaliplatin, PCI peritoneal cancer index,
RR reoperation rate; aincludes 13 % appendix cancer; b18 % early postoperative intraperitoneal chemotherapy (EPIC) alone; c24 % EPIC alone
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Oncology of the Oost-Limburg Hospital in Genk, and the
Clinic of Digestive Surgical Oncology of Jules Bordet
Institute in Brussels. The trial will, however, be open
to participation by additional centers.
Study objectives and endpoints
The objective of the BEV-IP study is to assess the safety
and efficacy of perioperative combination chemotherapy
with BEV in colorectal PC patients treated with CRS
and IPC. The primary (composite) endpoint is three
month surgical morbidity and mortality, calculated using
the Dindo-Clavien classification [38]. Specifically, the
endpoint will be considered reached whenever a grade
IIIb or higher grade complication is reached. Secondary
endpoints include other (minor) morbidity, chemotherapy
related toxicity, treatment completion rate, pathological
response, PFS (defined as the time interval between start
of protocol treatment and disease progression or death),
and OS (calculated from start of protocol treatment until
death). In addition, translational research will be per-
formed on blood, serum, peritoneal fluid, and tumor tissue
samples obtained at various time points.
Inclusion criteria
Eligible patients suffer from synchronous or metachro-
nous biopsy proven peritoneal metastases from colorectal
origin. The following inclusion criteria should be met: age
over 18 years, Karnofsky index > 70 %, adequate mental
faculty allowing to understand the proposed treatment
protocol and provide informed consent, estimated life
expectancy > 6 months, absence of any other concurrent
malignant disease, serum creatinine ≤ 1.5 mg/dl or a
calculated glomerular filtration rate ≥ 60 mL/min/1.73 m2,
serum total bilirubin ≤ 1.5 mg/dl except for known
Gilbert’s disease, platelet count > 100,000/μl, hemoglobin >
9 g/dl, neutrophil granulocytes > 1,500/ml, International
Normalized Ratio ≤ 2, absence of alcohol and/or drug
abuse, no inclusion in other clinical trials interfering with
the study protocol, no concurrent chronic systemic im-
mune therapy, chemotherapy or hormone therapy not in-
dicated in the study protocol, absence of any severe organ
insufficiency, no pregnancy or breast feeding, adequate
contraception in fertile patients and written informed con-
sent. In addition, the disease should be deemed optimally
resectable (CC-0 or CC-1) with preservation of an ad-
equate quality of life. The estimated peritoneal cancer
index should ideally not exceed 25, but the location and
distribution of peritoneal spread are often more important
than the size and number of implants.
Patients with severe or uncontrolled cardiac pathology,
including recent (<6 months) occurrence of myocardial
infarction, the presence of congestive cardiac failure, of
symptomatic angor pectoris despite optimal medical
care, of cardiac arrhythmia requiring medical treatment
with insufficient rhythm control, or uncontrolled arterial
hypertension are excluded. Further exclusion criteria are
active bacterial, viral or fungal infection, active gastro-
duodenal ulcer, parenchymal liver disease (any stage cir-
rhosis), uncontrolled diabetes mellitus, severe obstructive
or restrictive respiratory insufficiency, psychiatric path-
ology capable of affecting comprehension and judgment
faculty, tumor in the presence of obstruction, evidence of
extra-abdominal disease or extensive liver metastasis, and
known allergy to any of the trial related drugs.
Interventions
Figure 1 illustrates the flowchart of all trial related
procedures.
Staging procedures
Clinical staging will include at least CT scan of the chest
and abdomen with itravenous (IV) and oral contrast and
measurement of carcinoembryonic antigen (CEA). Add-
itional imaging such as 18F-FDG-PET-CT, MRI, or diffusion
weighted (DWI) - MRI are optional. Peritoneal disease ex-
tent is scored according to Sugarbaker’s peritoneal cancer
index (PCI, score 0–39) [39]. Patients meeting the inclusion
criteria are planned for diagnostic laparoscopy, which is
recommended in all patients. The aim of laparoscopy is to
obtain tumor tissue for diagnostic confirmation and for
translational research. In addition, it may confirm resect-
ability by allowing inspection of the peritoneal surfaces,
specifically at the small bowel surface and mesentery.
Fig. 1 Flowchart of the BEV-IP study
Willaert et al. BMC Cancer  (2015) 15:980 Page 4 of 8
Alternatively, a tissue diagnosis may be obtained by translu-
minal or transparietal punction biopsy.
Neoadjuvant therapy
Neoadjuvant therapy consists of a combination of 5-
fluorouracil or capecitabine, oxaliplatin or irinotecan,
and bevacizumab for a total of 6 biweekly administra-
tions. The exact drug dose and schedule is according to
local practice, but typically includes oxaliplatin at a dose
of 85–100 mg/m2, irinotecan 180 mg/m2, and BEV
5 mg/kg. In patients with extensive abdominal wall
metastatic implants, radiotherapy may be considered in
addition to chemotherapy.
Response assessment
Therapy response is assessed after 3 therapy cycles
(6 weeks of treatment) by clinical examination, CEA
measurement, and CT scan of the chest and abdomen.
Other imaging modalities are optional. Patients with
clinical signs or symptoms of disease progression (e.g.
malignant ascites, ureteral stenosis or bowel obstruction)
are excluded. In patients with measurable peritoneal le-
sions, response will be graded according to the RECIST
1.1 criteria: (1) complete response (CR), (2) partial re-
sponse (PR, at least 30 % decrease in the sum of diame-
ters of target lesions), (3) stable disease (SD) and (4)
progressive disease (PD, new lesions or at least 20 %
increase in the sum of diameters of target lesions) [40].
Patients with response or stable disease are continued
on the same treatment until 6 cycles. Upon completion
of the neoadjuvant treatment schedule, a second response
assessment is perfomed using biochemistry, imaging, and
clinical assessment. Toxicity from neoadjuvant therapy
will be recorded and scored using the Common Termin-
ology Criteria for Adverse Events (CTCAE) version 4.0
[41]. In responding patients, surgery and IPC are planned
within 6–8 weeks completion of neoadjuvant therapy. A
minimal interval of 6 weeks between the last dose of BEV
and surgery will be respected.
Surgery and chemoperfusion
Peritoneal ascites or samples from peritoneal lavage with
saline are obtained for VEGF analysis before and after
CRS. The abdomen is explored systematically and CRS
proceeds if all disease is deemed resectable and a PCI ≤ 25
is confirmed. Tumor tissue samples (2×5 mm3) are ob-
tained and snap frozen for translational research. The re-
sult of CRS will be scored according to the completeness
of cytoreduction (CC) score: CC-0, no visible residual
tumour; CC-1, residual tumour nodules ≤ 2.5 mm in
diameter; CC-2: residual tumor nodules between 2.5
mm and 2.5 cm, and CC-3, residual disease > 2.5 cm
in size [42]. Intraperitoneal chemoperfusion is performed
according to local preference; the open method (coliseum)
is preferred. Oxaliplatin (200–460 mg/m2) in dextrose
5 % (2 liter/m2) is administered IP immediately following
5-FU 400 mg/m2 IV and LV 20 mg/m2 IV. Perfusion
temperature and duration of IPC are according to local
preference. Postoperative complications are recorded
during a period of three months postoperatively and
scored according to the Dindo-Clavien classification.
Pathology reporting
Specific attention will be paid to analysis of preoperative
chemotherapy response of the primary and/or the periton-
eal metastases. Tumor regression will be scored according
to the tumor regression grade (TRG) as described by
Rubbia-Brandt: TRG1, absence of tumor cells replaced by
abundant fibrosis; TRG2, rare scattered residual tumor
cells and abundant fibrosis; TRG3, a large amount of re-
sidual tumor cells with predominant fibrosis; TRG4,
tumor cells predominating over fibrosis; and TRG5, al-
most exclusively tumor cells without fibrosis [43]. In
addition, the mean percentages of necrosis and fibrosis
are assessed separately according to published methods
[44]. In patients with synchronous PC, the primary tumor
will be staged according to the 7th edition of the UICC/
AJCC TNM staging system.
Follow-up
Within 4–6 weeks postoperatively, baseline measure-
ment of CEA and a CT scan of the chest and abdomen
are performed. Adjuvant chemotherapy is initiated from
6–8 weeks postoperatively, with a maximum interval
since the time of surgery of three months. Six additional
cycles of adjuvant chemotherapy are administered, identi-
cal to the neoadjuvant therapy. Reassessment with CEA
measurement and CT scan of the chest and abdomen are
performed after completion of the adjuvant chemotherapy
course. Further assessments using biochemistry, imaging,
and clinical evaluation are planned 3, 6, 9, 12, 18, and
24 months after completion of adjuvant chemotherapy.
Progressive patients are managed according to local
standard of care.
Patient reported outcomes
Health related quality of life (HRQOL) is an import-
ant endpoint in trials investigating novel therapies in
patients with metastatic cancer. The EORTC QLQ C-
30 and SF-36 questionnaires will be taken at different
time points: after inclusion (but before start of neoad-
juvant therapy), the day before surgery, and at post-
operative month 3, 6, 12, 18, and 24. The EORTC
questionnaires will be scored according to the scoring
manual (EORTC, third edition, 2001). The 36-Item
Short Form Health Survey (SF-36, RAND health) will
be scored according to the instructions from RAND
Health (2009 version).
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Translational research
Translational research will be aimed at identifying
biomarkers that predict response and toxicity to BEV
containing chemotherapy. Standard histology and im-
munohistochemistry is used to analyze microvessel
density and maturation as well as protein expression
of VEGF-A and HIF-1. Molecular biology techniques
will include gene expression of VEGF, VEGFR1, TSP-2,
and EGFR, mutation status of KRAS/NRAS/BRAF, and
germline polymorphisms (SNP’s) in VEGF dependent
angiogenesis pathways. In addition, circulating (serum)
biomarkers will be measured including VEGF, soluble
VEGFR-2, VEGF-C, VEGF-D, PlGF, bFGF, HGF, SDF-1,
MCP-3, Ang-2, IL-6, and IL-8. In peritoneal fluid samples,
peritoneal VEGF concentrations are measured. In addition,
we will analyze circulating tumor cells, circulating endo-
thelial cells, circulating endothelial progenitor cells, and
circulating exosomes.
Statistical considerations
The sample size (n = 45) was calculated to allow the esti-
mation of the primary endpoint with sufficiently narrow
confidence intervals to inform further development.
Three month morbidity and mortality rates reported
from studies or reviews of similar approaches but with-
out BEV, ranged from 23 to 31 %, and from 3 to 4 %, re-
spectively. Based on the literature, we expect to observe
a morbidity rate of 27 % and a mortality rate of 3.5 %.
Using effect methods, the proposed sample size will pro-
vide 95 % confidence intervals of about 14 %–40 % and
0.8 %–14 % for morbidity and mortality, respectively. In
general, morbidity rates as well as the fraction of oper-
ated patients who receive postoperative chemotherapy
will be estimated to ± 14 % or better. A total of 60 pa-
tients will be included in order to account for the esti-
mated drop-out rate of 33 %. Patients will be followed
up for 24 months postoperatively. Anonymized individ-
ual patient data will be extracted from the medical rec-
ord onto paper case report forms (CRF). The local
investigator will also report all adverse events in the
source documents and CRFs. The serious adverse events
will be reported within time periods specified in the
protocol. Given the uncertainty of potential operative
complications caused by BEV, an interim analysis is
planned after each additional cohort of 10 patients is in-
cluded in the study. The study will be terminated when
the observed major morbidity rate is >40 % and/or in
hospital mortality is >14 % at any given point in time.
Ethical considerations
The study will be conducted in agreement with either
the Declaration of Helsinki (Tokyo, Venice, Hong Kong,
Somerset West and Edinburgh amendments) or the laws
and regulations of the country, whichever provides the
greatest protection of the patient. The protocol was writ-
ten, and the study will be conducted according to the
international conference on harmonization guidelines for
Good Clinical Practice (ICH-GCP). The protocol was ap-
proved on May 13, 2015 by the Ethical Committee of
Ghent University Hospital. All data collected on a patient’s
health for the purpose of research will be kept confiden-
tial. The patient’s identity will never be disclosed.
Discussion
The concept of cytoreductive surgery and intraperitoneal
chemoperfusion has significantly improved the outlook
of patients with pseudomyxoma peritonei originating
from mucinous appendiceal neoplasms [45]. It was
therefore rational to expand the use of CRS and IPC to
PC from colorectal cancer, notwithstanding the less
favourable disease biology. Although significant pro-
longation of PFS may be achieved in selected patients,
recurrence after CRS and IPC is common. Braam and
coworkers reported that, even after complete cytoreduc-
tion and HIPEC, 73 % of all patients recurred [46]. Iso-
lated peritoneal recurrence was noted in 43 % of these
patients while 57 % developed systemic disease with or
without peritoneal recurrence. At the same time, sys-
temic therapy for metastatic CRC has improved consid-
erably over the past decades. Even though the response
of peritoneal metastases is often less pronounced com-
pared to solid organ metastases, there is little doubt that
modern chemotherapy is active against PC from colorec-
tal origin. Kerscher et al. noted that, over the past two
decades, the OS of PC patients has improved from 7 to
18 months concurrent with increasing use of active
chemotherapy regimens [47]. In a retrospective analysis
of 115 PC patients treated with preoperative irinotecan
or oxaliplatin based chemotherapy followed by CRS and
IPC, Passot and coworkers demonstrated a complete
and major pathological response rate of the peritoneal
disease in 10 % and 20 % of patients respectively [48]. In
addition, they demonstrated that among the various
chemotherapy lines used, FOLFOX with BEV resulted in
the best OS, a finding which was also reported by our
own group [49]. Given the high risk of recurrence and
the expected activity against peritoneal disease, peri-
operative chemotherapy with BEV may result in a bene-
fit similar to the setting of colorectal liver metastases
[50]. The drawback of neoadjuvant chemotherapy is that
patients who do not respond may progress and eventu-
ally become unresectable. However, it may be argued
that this scenario points to an unfavourable disease biol-
ogy in patients who would not benefit from extensive
surgery anyway, but would better be treated with alter-
native systemic treatment. In addition, the reported rates
of serious BEV-related postoperative adverse events are
low, if a time to surgery of 5–6 weeks is respected [37].
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The addition of BEV to first- or second-line 5-FU-based
chemotherapy increases PFS and OS [24]. Moreover,
neoadjuvant combination therapy with BEV improves
regression of CRC liver metastases and lowers the IP
VEGF level [33]. Intraperitoneal administration of BEV
has some activity in the palliation of malignant ascites
[28–30]. Furthermore, research in peritoneal metastatic
mice models shows that BEV inhibits the growth of peri-
toneal nodules and ascites [31]. Hence, an intensified
perioperative therapy with doublet chemotherapy plus
BEV may downstage the disease before performing CRS,
limit the extensiveness of surgery, increase the rates of
CC-0/1 resection, and improve control of locoregional
and distant recurrence.
The BEV-IP trial is the first to investigate the safety
and efficacy of perioperative combination chemotherapy
with BEV in combination with CRS and IPC with OX in
patients with synchronous or metachronous peritoneal
carcinomatosis from CRC. The results will help to define
the place of systemic chemotherapy combined with
anti-angiogenic treatment in the perioperative setting
in patients with PC from colorectal orgin who are
candidates for CRS and IPC.
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